ICM (Montpellier Cancer Institute)

What ICM (Montpellier Cancer Institute) does

ICM (Institut du Cancer de Montpellier / Montpellier Cancer Institute) is a French private non-profit Centre de Lutte Contre le Cancer (CLCC) within the Unicancer federation, headquartered at 208 Avenue des Apothicaires in the Euromédecine park, Montpellier, France. Founded approximately a century ago (celebrating its 100th anniversary in 2025-2026 under the brand "Centre Val d'Aurelle — Unicancer"), the institute operates as a single-site Comprehensive Cancer Center with 501-1,000 staff, integrating cancer care, clinical and translational research, prevention, and professional training. It treats adult and pediatric patients across all major oncologic pathologies — breast, digestive, gynecologic, urologic, thoracic, ENT, neurological, sarcoma/GIST, hematologic, melanoma and pediatric — and serves as the regional referral center for eastern Occitanie for pediatric radiotherapy, brachytherapy, and second-opinion tele-expertise.

The clinical technology stack is unusually deep for a single site: two Da Vinci surgical robots (ICM is the European reference center for oncologic robotic surgery with a training mission), six linear accelerators including the ViewRay MRIdian MRI-guided LINAC, two Ethos adaptive-radiotherapy systems, the only Calypso GPS-like tumor-tracking system in France, IntraBeam intraoperative radiotherapy, PDR/HDR brachytherapy, and HIPEC/CHIP and PIPAC intraperitoneal chemotherapy platforms (more than 1,000 cumulative procedures). Research is anchored by the co-located IRCM (Institut de Recherche en Cancérologie de Montpellier) and the SIRIC Montpellier Cancer integrated research site running the PRIORITY (colorectal), PANACEA (applied radiobiology) and ENERGY (genome integrity) programs, supported by an integrated clinical-research infrastructure (DRCI, CRC, CIPP, COMERE, UEPP, URT, CRB, Biométrie unit, Epidaure prevention).

ICM's revenue model is anchored on public hospital reimbursement by the French Assurance Maladie through the T2A (Tarification à l'Activité) tariff system for inpatient stays, day-hospital chemotherapy, surgery, radiotherapy, imaging, and nuclear-medicine examinations. A second stream comprises philanthropic income — one-time donations, regular donations, IFI (real-estate wealth tax) giving, bequests, life-insurance policies and corporate mécénat — channeled through the iRaiser donation portal. A third stream is competitive research funding via SIRIC Montpellier Cancer, Cancéropôle GSO, Réseau SO-RISP, and partnerships with IRCM. Clinical pricing is not publicly disclosed; patients' out-of-pocket cost depends on French social-security coverage plus complementary mutuelle insurance. As a not-for-profit CLCC within the Unicancer network, ICM has no equity capital structure; control is institutional, with senior leadership appointed by the French Ministry of Health (Pr Marc Ychou reconducted for a third term as Director in 2026). Customer segments span cancer patients, healthcare professionals and external referring institutions, donors/legators/corporate mécènes, and the general public for prevention campaigns led by the Epidaure department.

Name

ICM (Montpellier Cancer Institute)

Legal name

Institut du Cancer de Montpellier (ICM)

Website

https://icm.unicancer.fr

Company type

Private

Founded year

1925

Operating status

Operating

Headcount range

501–1,000 employees

Short description

ICM (Institut du Cancer de Montpellier) is a French non-profit Comprehensive Cancer Center (CLCC) in the Unicancer network that delivers integrated cancer care, research, prevention and training to adult and pediatric patients across the Occitanie region from a single-site facility in Montpellier.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Center / Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Offices of Physicians (62111), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093), Services-Hospitals (8060), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Surgical Oncology (HLAKAFAG), Gynecologic Oncology (HLAKAFAF), Oncology Telemedicine Platforms (HLALAGAH), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC)

Keywords

• Oncology hospital services
• Radiation oncology therapy
• Surgical oncology treatment
• Cancer research institute
• Cancer prevention programs

Headquarters

HQ city

Montpellier

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales, Others

Revenue model

1. Public hospital clinical-services revenue (T2A billing): Core funding as a French public Comprehensive Cancer Center (CLCC) within the Unicancer network, reimbursed by the French Assurance Maladie through the T2A (Tarification à l'Activité) model for inpatient stays, day-hospital sessions, surgical procedures, radiotherapy, imaging and nuclear-medicine examinations.
2. Philanthropy: donations, bequests and corporate mécénat: Voluntary income stream comprising one-time donations, regular donations, IFI (real-estate wealth tax) donations, bequests (legs), donations du vivant, life-insurance policies, and corporate mécénat - tax-deductible under French law and used to finance research, equipment and innovation projects not covered by standard hospital funding.
3. Research grants and SIRIC programs: Competitive research funding via SIRIC Montpellier Cancer (PRIORITY, PANACEA, ENERGY programs), Cancéropôle GSO, Réseau SO-RISP, and partnerships with IRCM, supporting fundamental, translational, clinical, methodological, prevention and SSH research.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

ICM is a French public Comprehensive Cancer Center (Centre de Lutte Contre le Cancer) delivering integrated oncology care, research, prevention and training at a single site in Montpellier. Its offering spans surgical oncology (Da Vinci robotics, HIPEC, PIPAC), medical oncology (day-hospital chemotherapy, early-phase trials), radiation oncology (external, intraoperative and brachytherapy), nuclear medicine, imaging, anatomopathology, pharmacy, anesthesia and supportive care, complemented by the IRCM research institute, SIRIC Montpellier Cancer research site, Epidaure prevention department and Ecole du Cancer de Montpellier training school.

Product overview

ICM (Institut du Cancer de Montpellier) is a French Comprehensive Cancer Center (Centre de Lutte Contre le Cancer) belonging to the Unicancer network, providing a unified oncology care, research, prevention and training offering rather than a modular commercial product. Its care offering is organized around multiple medical departments — including Radiothérapie oncologique, Médecine oncologique, Chirurgie oncologique, Anesthésie, Anatomopathologie, Pharmacie, Médecine nucléaire, Imagerie médicale and Soins de support — that operate together to deliver integrated patient pathways. Research is anchored by the Institut de Recherche en Cancérologie de Montpellier (IRCM) and the SIRIC Montpellier Cancer site, while prevention is delivered through the Epidaure department and training through the Ecole du Cancer de Montpellier (ECM). Adjacent professional services such as OncoPro (a phone line for healthcare professionals) and the Omnidoc tele-expertise platform extend these core activities, and a Cureety remote monitoring solution has been deployed at the day hospital to reinforce patient pathway safety.

Differentiator

Problem solved

Functional benefit

Brands

• Epidaure: Cancer prevention department of ICM
• Ecole du Cancer de Montpellier
• IRCM
• SIRIC Montpellier Cancer

Products and services

• Radiothérapie oncologique (Radiation oncology department) Provides external radiotherapy, intraoperative radiotherapy (IntraBeam), and brachytherapy for cancer patients; the only facility in eastern Occitanie offering pediatric radiotherapy and the recognized referral center for brachytherapy in the region.
• Médecine oncologique (Medical oncology department) Provides ambulatory chemotherapy in a 38-place day hospital, short-stay hospitalization, palliative care, and the Unité d'Essais de Phases Précoces (UEPP) for early-phase clinical trials of innovative molecules.
• Chirurgie oncologique (Surgical oncology department) Provides cancer surgery with 11 operating rooms including two Da Vinci surgical robots, 2 ambulatory rooms, 1 endoscopy room, 1 brachytherapy room and a 15-post SSPI; ICM is the European reference center for oncologic robotic surgery and an international expert center for HIPEC (CHIP) and PIPAC procedures.
• Anesthésie et médecine intensive (Anesthesia and intensive care) Provides anesthesia and intensive care for surgical patients before, during, and after operations, as well as medical patients during endoscopies, radiology and radiotherapy procedures.
• Anatomie et cytologie pathologique (Pathology) Provides formal diagnosis of tumor lesions and characterization of morphological features including benign/malignant status, aggressiveness and excision margins.
• Pharmacie (Pharmacy) Ensures safety of the medication and medical-device supply chain: procurement, manufacturing and quality control of injectable anti-cancer drugs, dispensing, and patient counseling.
• Médecine nucléaire (Nuclear medicine) Provides PET scans, cardiac and bone scintigraphy, breast lymphoscintigraphy and other nuclear medicine procedures; regional reference center 'TUTHYREF' for refractory thyroid tumors.
• Imagerie médicale (Diagnostic and interventional imaging) Provides diagnostic and interventional imaging organized around senology, standard radiology and ultrasound, CT scanner, and MRI for cancer patients.
• Soins de support (Supportive care) Provides holistic patient management addressing patients' life, family, personal and professional projects while ensuring well-being and continuity with local healthcare professionals.
• Institut de Recherche en Cancérologie de Montpellier (IRCM) Foundational research institute covering fundamental, translational, clinical, technological innovation, methodological, preventive, and human/social sciences research, integrated within ICM and part of the SIRIC Montpellier Cancer site.
• Epidaure - Département de prévention Cancer prevention department running programs on alcohol, tobacco, physical activity, nutrition, and solar protection (e.g., SoftPeers, Mois sans tabac, EpiMoove, PRISME) as well as a ludo-educational space and intervention research.
• Ecole du Cancer de Montpellier (ECM) Cancer education and training school providing labeled training programs to healthcare professionals, with a dedicated teaching team and structured curricula in oncology.
• SIRIC Montpellier Cancer Integrated cancer research site (Site de Recherche Intégrée sur le Cancer) running programs PRIORITY (colorectal cancer), PANACEA (applied radiobiology in oncology) and ENERGY (genome integrity).
• OncoPro (dedicated phone line for healthcare professionals) Dedicated telephone line for healthcare professionals to address clinical questions, advise on patient care, and coordinate with ICM specialists.
• Miroki (companion robot for pediatric radiotherapy) Humanoid companion robot developed by Enchanted Tools, deployed in pediatric radiotherapy sessions where no human presence is possible in the treatment room, providing interactive emotional support to children.
• Ethos adaptive radiotherapy accelerator service

Quantifiable outcome

• 4,781 surgical interventions in 2019 (2,587 surgical patients, 1,019 breast surgeries, 290 robot-assisted, 82 HIPEC)
• +7 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability1 record

Feature10 records

Partnerships

18 partnerships are on record, tiered flagship / network-level, major clinical-academic, major clinical, flagship research, core / flagship digital-health partnership, core / specialty, core digital-health platform, core regional professional-union partnership, core regional network, flagship technology vendor, flagship surgical-robotics partner, core regional research network, secondary research network, specialty network, community / donor ecosystem and minor content reference.

• Unicancerflagship / network-levelStrategic or Co-development PartnerICM is one of the French Comprehensive Cancer Centers (CLCCs) within the Unicancer network, the only French hospital network 100% dedicated to cancer. Unicancer provides the network brand, shared commitments and a patient charter followed by all CLCCs, and the logo is shown in the footer of the ICM website.
• CHU de Montpelliermajor clinical-academicStrategic or Co-development PartnerAcademic-hospital partner in the phase-2 RCMI-GI clinical trial evaluating the Calypso GPS-like real-time tracking system for prostate radiotherapy.
• Clinique Beau Soleilmajor clinicalStrategic or Co-development PartnerPrivate-clinic partner co-conducting the RCMI-GI phase-2 trial of the Calypso real-time tumor-tracking system in prostate radiotherapy alongside CHU Montpellier.
• IRCM (Institut de Recherche en Cancérologie de Montpellier)flagship researchStrategic or Co-development PartnerICM's fundamental-research arm, the IRCM, is co-located within the institute and operates the technical platforms (plateaux techniques) supporting ICM's translational and clinical research programs.
• SIRIC Montpellier Cancerflagship researchStrategic or Co-development PartnerIntegrated cancer-research site (SIRIC) running three research programs: PRIORITY (colorectal cancer), PANACEA (radiobiology applied to oncology) and ENERGY (genome integrity), hosted at ICM.
• Cureetycore / flagship digital-health partnershipTechnology or IntegrationDigital-health partner providing remote-monitoring (télésurveillance) for ICM's day-hospital patients, deployed in 2026 to reinforce safety of the care pathway for hospital-of-day patients.
• Enchanted Toolscore / specialtyTechnology or IntegrationRobotics partner whose Mirokaï humanoid robots are deployed at ICM as companion robots for children undergoing radiotherapy, providing interactive emotional support during sessions.
• Omnidoccore digital-health platformTechnology or IntegrationTele-expertise platform in oncologic surgery adopted by ICM to enable external physicians to request surgical second-opinions and exchange with ICM specialists.
• URPS Médecins Occitaniecore regional professional-union partnershipStrategic or Co-development PartnerSigned a partnership convention on 4 June 2026 with ICM to coordinate city-hospital cancer care across Occitanie and engage private-practice physicians.
• Réseau Onco-Occitaniecore regional networkStrategic or Co-development PartnerRegional oncology network coordinating cancer care in Occitanie; ICM's nuclear-medicine and medicine departments collaborate via this network for complex cases.
• Varian Medical Systems (a Siemens Healthineers company)flagship technology vendorTechnology or IntegrationEquipment vendor supplying the Calypso GPS-like real-time tumor-tracking system (only one in France) and the Ethos adaptive-radiotherapy linear accelerators used at ICM.
• Intuitive Surgical (Da Vinci)flagship surgical-robotics partnerOEM/ Whitelabel/ Licensing PartnerManufacturer of the two Da Vinci surgical robots installed at ICM; ICM is the designated European reference center for oncologic robotic surgery, with a mission to train French and international surgeons.
• ViewRayflagship technology vendorTechnology or IntegrationManufacturer of the MRIdian MRI-guided LINAC installed at ICM, the first MRI-guided radiotherapy system in the institute and used for real-time soft-tissue tracking during irradiation.
• Cancéropôle GSO (Grand Sud-Ouest)core regional research networkStrategic or Co-development PartnerInter-regional cancer-research pole covering the Grand Sud-Ouest; ICM hosts the 22nd annual Journées du Cancéropôle GSO in November 2026 and participates in the prevention-research network.
• Réseau SO-RISPsecondary research networkStrategic or Co-development PartnerNational research network on primary and secondary cancer prevention, in which ICM's Epidaure prevention department participates.
• Institut Gustave Roussy (IGR) - TUTHYREF networkspecialty networkStrategic or Co-development PartnerICM's nuclear-medicine department is a regional expert center in TUTHYREF, the national network for refractory thyroid tumors piloted by IGR.
• Partner patient associations (Associations partenaires)community / donor ecosystemOthersNetwork of patient-support associations (cancer du sein, prostate, etc.) co-located and co-promoted with ICM, listed on a dedicated 'Associations partenaires' page and supporting patients, caregivers and outreach events.
• ESSO (European Society of Surgical Oncology)minor content referenceOthersESSO is the source of the surgical-oncology infographic (Chirurgie esso-infographic-in-french.pdf) downloaded from the ICM surgical-oncology page.

Scale indicators23 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Institut Curie: Paris-based CLCC and historic cancer research hospital combining a hospital, research center and museum; operates an identical Unicancer-style integrated care-research-training model and competes with ICM for advanced oncology referrals, clinical trials and KOL recognition.
• IUCT Oncopole (Institut Universitaire du Cancer de Toulouse): Toulouse-based comprehensive cancer center within the Claudius Regaud / CHU Toulouse structure, serving the western Occitanie region; competes with ICM directly for Occitanie radiotherapy, surgical-oncology and clinical-trial referrals.
• Institut Gustave Roussy (IGR): France's largest and leading Comprehensive Cancer Center (CLCC) in Villejuif, with a comparable integrated care-research-prevention-training model and a broader national/international catchment. IGR also pilots the TUTHYREF refractory-thyroid network in which ICM is a regional expert center, making it a direct network-level peer.
• Centre Léon Bérard (CLB): Lyon-based Unicancer CLCC providing the same full continuum of cancer surgery, medical oncology, radiotherapy, research (CRCL/CLB) and prevention services; directly comparable in scope, technology stack and CLCC governance, and a peer for Occitanie patients seeking tertiary care.
• Centre Georges-François Leclerc (CGFL): Dijon-based Unicancer CLCC offering comprehensive cancer care with a strong research and early-phase trial orientation; comparable in scale and CLCC model, and a relevant network peer for academic clinical research benchmarking.
• Institut Paoli-Calmettes (IPC): Marseille-based Unicancer CLCC with the same comprehensive cancer-center model — surgery, radiotherapy, medical oncology, research and prevention — and a comparable regional monopoly dynamic in Provence-Alpes-Côte d'Azur; a natural network peer for benchmarking.
• Centre François Baclesse: Caen-based Unicancer CLCC in Normandy, focused on radiotherapy, medical oncology and surgery with a strong research arm (INSERM U1086); a directly comparable single-region CLCC peer in terms of scope, governance and technology positioning.
• ICO (Institut de Cancérologie de l'Ouest): Multi-site French CLCC (Angers/Nantes) offering the same Unicancer model of integrated cancer care, research and prevention; comparable technology platform and patient-throughput scale, and a relevant benchmark for two-site vs. single-site CLCC strategy.

Regional players

• CHU de Montpellier: Adjacent academic hospital partner (co-investigator on the RCMI-GI Calypso prostate trial) and partial regional competitor for hematology, complex surgery and clinical-trial patients in the Montpellier metro; relevant as a city-hospital cooperation/competition peer.

Broad incumbents

• The Royal Marsden NHS Foundation Trust: UK's flagship comprehensive cancer center with integrated research (ICR) and a long tradition of technology adoption (e.g., MRIdian, Da Vinci training); a useful international benchmark for technology-led CLCC economics and the European reference-center dynamic that ICM aspires to in robotic surgery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ICM_Montpellier

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICM (Montpellier Cancer Institute)